Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Verneris

Showing results (161-170 of 180) with videos related to

Pageof 18
Sort By:
The Journal of Experimental Medicine|May 2, 2019
A novel human <i>IL2RB</i> mutation results in T and NK cell-driven immune dysregulationIsabel Z Fernandez, Ryan M Baxter, Josselyn E Garcia-Perez, et al.
Journal for Immunotherapy of Cancer|August 6, 2021
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemiaJohn E Levine, Stephan A Grupp, Michael A Pulsipher, et al.
Blood Advances|November 13, 2019
More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modelingPeter Bader, Emilia Salzmann-Manrique, Adriana Balduzzi, et al.
Blood Advances|April 28, 2022
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cellsAdam J Lamble, Regina M Myers, Agne Taraseviciute, et al.
Blood Advances|August 8, 2022
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortiumHeather E Stefanski, Anne Eaton, Christina Baggott, et al.
Blood Advances|November 18, 2021
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium ReportVanessa A Fabrizio, Christine L Phillips, Adam Lane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2022
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic LeukemiaLiora M Schultz, Anne Eaton, Christina Baggott, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 2, 2015
Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant ResearchMichael J Burke, Michael R Verneris, Jennifer Le Rademacher, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 24, 2018
Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute LeukemiaTroy C Lund, Kwang Woo Ahn, Heather R Tecca, et al.
Blood Advances|May 17, 2022
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemiaAmy Moskop, Lauren Pommert, Christina Baggott, et al.
Pageof 18

Showing results (161-170 of 180) with videos related to

Sort By:
Pageof 18
The Journal of Experimental Medicine|May 2, 2019
A novel human <i>IL2RB</i> mutation results in T and NK cell-driven immune dysregulationIsabel Z Fernandez, Ryan M Baxter, Josselyn E Garcia-Perez, et al.
Journal for Immunotherapy of Cancer|August 6, 2021
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemiaJohn E Levine, Stephan A Grupp, Michael A Pulsipher, et al.
Blood Advances|November 13, 2019
More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modelingPeter Bader, Emilia Salzmann-Manrique, Adriana Balduzzi, et al.
Blood Advances|April 28, 2022
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cellsAdam J Lamble, Regina M Myers, Agne Taraseviciute, et al.
Blood Advances|August 8, 2022
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortiumHeather E Stefanski, Anne Eaton, Christina Baggott, et al.
Blood Advances|November 18, 2021
Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: a Pediatric Real World CAR Consortium ReportVanessa A Fabrizio, Christine L Phillips, Adam Lane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2022
Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic LeukemiaLiora M Schultz, Anne Eaton, Christina Baggott, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 2, 2015
Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant ResearchMichael J Burke, Michael R Verneris, Jennifer Le Rademacher, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 24, 2018
Outcomes after Second Hematopoietic Cell Transplantation in Children and Young Adults with Relapsed Acute LeukemiaTroy C Lund, Kwang Woo Ahn, Heather R Tecca, et al.
Blood Advances|May 17, 2022
Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemiaAmy Moskop, Lauren Pommert, Christina Baggott, et al.
Pageof 18